Teva Pharmaceutical Industries announced the exclusive first-to-file launch of a generic version of Eli Lilly’s Cialis tablets in the U.S.
First-to-file status grants Teva a 180-day period of market exclusivity before the FDA approves another generic.
The launch builds on the generic giant’s portfolio, and follows an exclusive launch of a generic version of Viagra. According to Teva, the drugmaker has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S.
Read the press release
[javascriptSnippet]